AR080908A1 - Formulaciones de un piridazin -bipirazinilo - Google Patents

Formulaciones de un piridazin -bipirazinilo

Info

Publication number
AR080908A1
AR080908A1 ARP110101288A ARP110101288A AR080908A1 AR 080908 A1 AR080908 A1 AR 080908A1 AR P110101288 A ARP110101288 A AR P110101288A AR P110101288 A ARP110101288 A AR P110101288A AR 080908 A1 AR080908 A1 AR 080908A1
Authority
AR
Argentina
Prior art keywords
bipirazinil
piridazin
formulations
bipirazinyl
dimetii
Prior art date
Application number
ARP110101288A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR080908A1 publication Critical patent/AR080908A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion farmacéutica de 2-[(R)-4-(6-bencil-4,5-dimetiI-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2H-[1,2']-bipirazinil-5'-il]-propan-2-ol.
ARP110101288A 2010-04-16 2011-04-14 Formulaciones de un piridazin -bipirazinilo AR080908A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32498010P 2010-04-16 2010-04-16
US36104010P 2010-07-02 2010-07-02

Publications (1)

Publication Number Publication Date
AR080908A1 true AR080908A1 (es) 2012-05-16

Family

ID=44170469

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101288A AR080908A1 (es) 2010-04-16 2011-04-14 Formulaciones de un piridazin -bipirazinilo

Country Status (3)

Country Link
AR (1) AR080908A1 (es)
TW (1) TW201202223A (es)
WO (1) WO2011130500A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
AU5152900A (en) * 1999-05-24 2000-12-12 Purepac Pharmaceutical Co. A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Also Published As

Publication number Publication date
WO2011130500A1 (en) 2011-10-20
TW201202223A (en) 2012-01-16

Similar Documents

Publication Publication Date Title
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
MY160727A (en) Oral formulations and lipophilic salts of methylnaltrexone
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
MX2009011165A (es) Formulaciones farmaceuticas que contienen derivados del acido lipoico.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
IN2015DN00885A (es)
PH12014502462A1 (en) Complement pathway modulators and uses thereof
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
IN2015DN00845A (es)
EA201170512A1 (ru) Композиция для перорального введения
AU2012280198A8 (en) Darunavir combination formulations
MX347373B (es) Soluciones anti-inflamatorias estables para inyección.
UY34295A (es) Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
MX341976B (es) Formulaciones de darunavir.
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.

Legal Events

Date Code Title Description
FB Suspension of granting procedure